• Leveljump Healthcare (JUMP) announced the company is acquiring a minority 13.1-per-cent stake Real Time Medical
  • Real Time is a private Ontario company founded by physicians with a vision to grow and operate a nationwide radiology collaboration service
  • The all-stock deal is worth approximately C$1.48 million
  • Real Time’s service network launched in 2008
  • LevelJump Healthcare is down 3.45 per cent, trading at $0.14 at 1:11 pm EST

Leveljump Healthcare (JUMP) announced the company is acquiring a minority 13.1-per-cent stake Real Time Medical.

Ontario-based Real Time is a private company founded and operated by physicians. Its vision is to grow and operate a nationwide radiology collaboration service for Canadian radiologists, with world-class, patented diagnostic workload balancing, workflow orchestration, peer learning and diagnostic operations software.

The all-stock deal is worth approximately C$1.48 million.

The equity interest in Real Time Medical was acquired through a mini-tender offer to that company’s shareholders on November 1, 2021.

“We are very excited about this investment and believe that with Real Time’s teleradiology operations and servicing in multiple provinces across Canada, that there is a natural complement to our core CTS operations. We are focused on expanding our telehealth solutions and offering critical care radiology support and this investment is another step in growing our company,” said Leveljump Chief Executive Officer Mitchell Geisler.

The closing of the deal remains subject to approval by the TSX Venture Exchange.

Toronto-based Leveljump is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology.

LevelJump Healthcare is down 3.45 per cent, trading at $0.14 at 1:11 pm EST.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.